Úplné zobrazení záznamu

Toto je statický export z katalogu ze dne 04.11.2023. Zobrazit aktuální podobu v katalogu.

Bibliografická citace

.
0 (hodnocen0 x )
EB
ONLINE
Cham : Springer International Publishing AG, 2021
1 online resource (363 pages)
Externí odkaz    Plný text PDF 
   * Návod pro vzdálený přístup 


ISBN 9783030632342 (electronic bk.)
ISBN 9783030632335
Print version: Vermorken, Jan B. Critical Issues in Head and Neck Oncology Cham : Springer International Publishing AG,c2021 ISBN 9783030632335
Cetuximab as Anti-EGFR Targeting Agent -- Mechanisms of Cetuximab Resistance -- Altered Response Elicited at the Level of EGFR -- Molecular Alterations in Effectors Downstream of EGFR -- Cross-talk with Other Receptor Tyrosine Kinases -- Alterations in Proteins Outside the EGFR Pathway -- Epithelial-to-Mesenchymal Transition -- Hypoxia and Angiogenesis -- Strategies to Overcome Cetuximab Resistance -- Irreversible and Multiple HER Receptor Inhibition to Overcome Resistance -- Identification of Drug Resistance Mechanisms and Predictive Biomarkers -- Conclusion and Future Perspectives -- References -- Chapter 4: The Role of Liquid Biopsies for Monitoring Disease Evolution -- Introduction -- Liquid Biopsies for Cancer Screening and Disease Monitoring -- Early Detection of Virally Associated HNSCC Based on Plasma DNA ---
Cell-free DNA Analysis in Non-virally Related HNSCC -- DNA Methylation Analysis for Cancer Screening -- Cell-Free Circulating Tumor DNA for Mutation Profiling.
Cetuximab as Anti-EGFR Targeting Agent -- Mechanisms of Cetuximab Resistance -- Altered Response Elicited at the Level of EGFR -- Molecular Alterations in Effectors Downstream of EGFR -- Cross-talk with Other Receptor Tyrosine Kinases -- Alterations in Proteins Outside the EGFR Pathway -- Epithelial-to-Mesenchymal Transition -- Hypoxia and Angiogenesis -- Strategies to Overcome Cetuximab Resistance -- Irreversible and Multiple HER Receptor Inhibition to Overcome Resistance -- Identification of Drug Resistance Mechanisms and Predictive Biomarkers -- Conclusion and Future Perspectives -- References -- Chapter 4: The Role of Liquid Biopsies for Monitoring Disease Evolution -- Introduction -- Liquid Biopsies for Cancer Screening and Disease Monitoring -- Early Detection of Virally Associated HNSCC Based on Plasma DNA ---
Intro -- Preface -- Contents -- Part I: Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) -- Chapter 1: Promising Biomarkers for Early Diagnosis and Prognosis Prediction -- Introduction -- Matrix Metalloproteinases -- Autophagy Biomarkers -- Intra-tumoural Immune Cells as Biomarkers -- References -- Chapter 2: Biomarkers for Hypoxia, HPVness, and Proliferation from Imaging Perspective -- Introduction -- Imaging Biomarkers for the Assessment of HPV-ness -- Imaging Biomarkers for Tumor Hypoxia -- Evaluation Treatment Response with RECIST 1.1 -- The Potential for Automatic Head and Neck Segmentation and Volumetric RECIST Assessment as Surrogate Imaging Marker for Tumor Proliferation -- Conclusions and Future Directions -- References -- Chapter 3: Mechanisms of Cetuximab Resistance and How to Overcome It -- Introduction -- The Epidermal Growth Factor Receptor ---
Chapter 6: Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) -- Background -- Potential Predictive Biomarkers for Immune Checkpoint Inhibitors -- PD-L1 -- Gene Expression Profiling -- Tumour Mutation Burden -- Combination of Tumour Mutation Burden and Gene Expression Profiling -- Multidimensional Quantitative IHC/IF -- Tissue Resident Memory (TRM) Cells -- Conclusion -- References -- Part II: Primary Disease -- Chapter 7: Novel Approaches in Surgical Management: How to Assess Surgical Margins -- Introduction -- Historical Background: The Concept of "Margin" -- Current Biological Rationale of Margins in Head and Neck Surgery -- Special Elements of Challenge in the Head and Neck Area -- Practical Determinants of Margin -- "Frailty" of Cutting Through Healthy Tissue -- Current Intraoperative Margin Evaluation -- Future Directions: "Know Your Enemy" ---
Emergence of Immune Therapies in HNSCC -- Second-Line Randomised Trials of Immune Checkpoint Inhibitors.
How to re-Irradiate? -- Re-Irradiation Dose -- Re-Irradiation Volume -- Concurrent Systemic Therapy -- Radiation Techniques -- Intensity-Modulated Radiotherapy (IMRT) -- Stereotactic Body Radiotherapy (SBRT) -- Proton Therapy -- Brachytherapy -- Toxicities of re-Irradiation -- References -- Chapter 18: New and Promising Targeted Therapies in First and Second-Line Settings -- Introduction -- EGFR Pathway -- Cetuximab -- Other ErbB Antibodies -- TKIs against ErbB -- Future Research into ErbB Targeting -- PI3K/AKT/mTOR Pathway -- Cell Cycle Regulation -- DNA Repair Inhibitors -- Antiangiogenesis -- RAS-RAF-MEK-ERK Pathway -- FGFR -- Neurotrophic Tyrosine Kinase Receptor Family -- Implications for Clinical Trial Design -- Conclusions -- References -- Chapter 19: Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer -- Background: Prior to the Emergence of Immune Therapies ---
Research in HPV(−) LAHNSCC -- Window of Opportunity Trials Exploring Targeted Agents, Including immunotherapy -- Hypoxia Modification and Smoking Cessation -- Patients Unfit for Chemotherapy -- Conclusion -- References -- Chapter 10: High-Dose Three-Weekly or Low-Dose Weekly Cisplatin during Radiation, What to Prefer? -- Introduction -- High-Dose Three-Weekly Cisplatin -- Low-Dose Weekly Cisplatin -- High-Dose Three-Weekly Versus Low-Dose Weekly -- Level V Evidence -- Level IV Evidence -- Level III Evidence -- Level of Evidence II -- Level of Evidence I -- Immunotherapy Trials -- Concluding Remarks and Outlooks for the Future -- References -- Chapter 11: Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer -- Introduction -- Milestones in Systemic Therapies for Locoregionally Advanced HNSCC ---
Chapter 8: The Surgical Approach to Elderly Patients with HNSCC -- Introduction -- Functional Physiological Age Related Issues with Impact on Selection for Surgical Treatment -- Assessment of Comorbidity for Surgical Treatment -- Age and Special Surgical Procedures -- Conclusion -- References -- Chapter 9: Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma -- Introduction -- Definition of LAHNSCC in HPV(+) HNC -- Trials on HPV(+) LAHNSCC -- Revisiting the Role of Cisplatin and Cetuximab in HPV(+) LAHNSCC -- Refining "Old Tools" for HPV(+) LAHNSCC: Dose, Fractionation, and Volumes -- Addressing Distant Metastasis Endpoint: Role of Induction Chemotherapy -- Quest for Additional Risk Stratification Parameters -- Emerging Role of Immunotherapy in HPV(+) LAHNSCC ---
First-Line Randomised Trials of Immune Checkpoint Inhibitors.
Part III: Recurrent and/or Metastatic Disease -- Chapter 16: Salvage Surgery in Head and Neck Cancer -- Introduction -- Evolution of Salvage Surgery -- Tumor Factors -- Patient Factors -- Reconstructive Surgery after Resection for Salvage -- Arterial and Venous Options for Reconstruction in a Salvage Neck -- Venous Options for Reconstruction in a Salvage Neck -- Advanced Options for Reconstruction in a Salvage Neck -- Complications in Salvage Surgery -- Ideal Candidates -- Conclusion -- References -- Chapter 17: Re-Irradiation for Local Relapses or Second Primaries: When and how? -- Introduction -- When to re-Irradiate? -- Previous Toxicity and Patient-Related Considerations -- Treatment Volume and Recurrent Stage -- Time Interval since Initial Radiotherapy -- Anatomical Site -- Second Primary vs Recurrent Tumors -- Re-Irradiation after Salvage Surgery ---
Chapter 6: Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) -- Background -- Potential Predictive Biomarkers for Immune Checkpoint Inhibitors -- PD-L1 -- Gene Expression Profiling -- Tumour Mutation Burden -- Combination of Tumour Mutation Burden and Gene Expression Profiling -- Multidimensional Quantitative IHC/IF -- Tissue Resident Memory (TRM) Cells -- Conclusion -- References -- Part II: Primary Disease -- Chapter 7: Novel Approaches in Surgical Management: How to Assess Surgical Margins -- Introduction -- Historical Background: The Concept of "Margin" -- Current Biological Rationale of Margins in Head and Neck Surgery -- Special Elements of Challenge in the Head and Neck Area -- Practical Determinants of Margin -- "Frailty" of Cutting Through Healthy Tissue -- Current Intraoperative Margin Evaluation -- Future Directions: "Know Your Enemy" ---
Comparison of the Practice Changing TPF Protocols (TAX 323/EORTC 24971 and TAX 324) -- When to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer -- For Larynx Preservation.
Emergence of Immune Therapies in HNSCC -- Second-Line Randomised Trials of Immune Checkpoint Inhibitors.
Future Directions: Enhanced Tumor Visualization -- Future Directions: Augmented Mapping of the Surgical Bed -- Conclusions -- References.
How to re-Irradiate? -- Re-Irradiation Dose -- Re-Irradiation Volume -- Concurrent Systemic Therapy -- Radiation Techniques -- Intensity-Modulated Radiotherapy (IMRT) -- Stereotactic Body Radiotherapy (SBRT) -- Proton Therapy -- Brachytherapy -- Toxicities of re-Irradiation -- References -- Chapter 18: New and Promising Targeted Therapies in First and Second-Line Settings -- Introduction -- EGFR Pathway -- Cetuximab -- Other ErbB Antibodies -- TKIs against ErbB -- Future Research into ErbB Targeting -- PI3K/AKT/mTOR Pathway -- Cell Cycle Regulation -- DNA Repair Inhibitors -- Antiangiogenesis -- RAS-RAF-MEK-ERK Pathway -- FGFR -- Neurotrophic Tyrosine Kinase Receptor Family -- Implications for Clinical Trial Design -- Conclusions -- References -- Chapter 19: Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer -- Background: Prior to the Emergence of Immune Therapies ---
References -- Chapter 14: Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer? -- Introduction -- Adjuvant Post-Operative Chemoradiotherapy Improves Outcomes in LA-SCCHN -- Adjuvant Chemotherapy Is Not Effective in LA-SCCHN -- Epidermal Growth Factor Receptor-Targeted Therapies in LA-SCCHN -- Anti-EGFR Monoclonal Antibodies Are Not Used as Adjuvant Therapies for LA-SCCHN -- Small Tyrosine Kinase Inhibitors Are Not Effective Adjuvant Therapies in LA-SCCHN -- Immune Checkpoint Inhibitors as Adjuvant Therapies in LA-SCCHN -- Summary and Conclusions -- References -- Chapter 15: Optimal Supportive Measures during Primary Treatment -- Introduction -- Reasons to Implement Supportive Care during Curative Treatment in Head and Neck Cancer -- Multiple Interventions for Different Aspects of Support ---
Research in HPV(−) LAHNSCC -- Window of Opportunity Trials Exploring Targeted Agents, Including immunotherapy -- Hypoxia Modification and Smoking Cessation -- Patients Unfit for Chemotherapy -- Conclusion -- References -- Chapter 10: High-Dose Three-Weekly or Low-Dose Weekly Cisplatin during Radiation, What to Prefer? -- Introduction -- High-Dose Three-Weekly Cisplatin -- Low-Dose Weekly Cisplatin -- High-Dose Three-Weekly Versus Low-Dose Weekly -- Level V Evidence -- Level IV Evidence -- Level III Evidence -- Level of Evidence II -- Level of Evidence I -- Immunotherapy Trials -- Concluding Remarks and Outlooks for the Future -- References -- Chapter 11: Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer -- Introduction -- Milestones in Systemic Therapies for Locoregionally Advanced HNSCC ---
The Example of Mucositis: An Early and up-to-Date Supportive Care Intervention -- Conclusion -- References.
Chapter 8: The Surgical Approach to Elderly Patients with HNSCC -- Introduction -- Functional Physiological Age Related Issues with Impact on Selection for Surgical Treatment -- Assessment of Comorbidity for Surgical Treatment -- Age and Special Surgical Procedures -- Conclusion -- References -- Chapter 9: Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma -- Introduction -- Definition of LAHNSCC in HPV(+) HNC -- Trials on HPV(+) LAHNSCC -- Revisiting the Role of Cisplatin and Cetuximab in HPV(+) LAHNSCC -- Refining "Old Tools" for HPV(+) LAHNSCC: Dose, Fractionation, and Volumes -- Addressing Distant Metastasis Endpoint: Role of Induction Chemotherapy -- Quest for Additional Risk Stratification Parameters -- Emerging Role of Immunotherapy in HPV(+) LAHNSCC ---
Concordance Between Liquid and Solid Tissue-Based Mutational Analysis -- ctDNA Versus CTCs: Which Is the Better Source for Mutation Analysis? -- Liquid Biopsies for Treatment Selection and the Analysis of Resistance Mechanisms -- Circulating Tumor Cells for Prognosis of Outcome in HNSCC -- Conclusions -- References -- Chapter 5: NK Cells in Immunotherapy: How Important Are They? -- Introduction -- NK Cells, Antitumor Effects and Antibody Dependent Cell Cytotoxicity -- Strategies to Enhance Antitumor NK Cell Function -- Reinforcement of NK Cell Activity -- Prevent NK Cell Inhibition -- Anti-PD-1 -- Anti NKG2A -- Anti KIR2 -- Anti TIM-3 -- Anti LAG-3 -- Anti-TIGIT -- Increase ADCC Through Engineering of Monoclonal Antibodies -- Improve NK Cells Trafficking and Homing in the Tumor -- CAR-NK -- Conclusions -- References ---
First-Line Randomised Trials of Immune Checkpoint Inhibitors.
For Treatment Intensification -- For Borderline Resectable or Unresectable Oral Cavity Cancer -- As a Selection Tool for RT Dose de-Escalation in HPV-Positive OPSCC -- Oligometastatic Disease -- Where to Use Induction Chemotherapy -- Conclusions -- References -- Chapter 12: Prognostic Role of p16/HPV in Non-oropharyngeal Head and Neck Squamous Cell Cancer (HNSCC) -- Introduction -- HPV Life Cycle -- Risk Factors for HPV(+) Non-OPC -- p16 as a Surrogate Biomarker for a Transcriptionally Active HPV Infection in Non-OPC -- p16/HPV as a Prognostic Factor in Non-OPC -- Conclusions -- References -- Chapter 13: Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy? -- Introduction -- Induction Therapy with Targeted Therapy and Immune Checkpoint Inhibitors -- Window of Opportunity Trials with Targeted Therapy and Immune Checkpoint Inhibitors -- Conclusion ---
Part III: Recurrent and/or Metastatic Disease -- Chapter 16: Salvage Surgery in Head and Neck Cancer -- Introduction -- Evolution of Salvage Surgery -- Tumor Factors -- Patient Factors -- Reconstructive Surgery after Resection for Salvage -- Arterial and Venous Options for Reconstruction in a Salvage Neck -- Venous Options for Reconstruction in a Salvage Neck -- Advanced Options for Reconstruction in a Salvage Neck -- Complications in Salvage Surgery -- Ideal Candidates -- Conclusion -- References -- Chapter 17: Re-Irradiation for Local Relapses or Second Primaries: When and how? -- Introduction -- When to re-Irradiate? -- Previous Toxicity and Patient-Related Considerations -- Treatment Volume and Recurrent Stage -- Time Interval since Initial Radiotherapy -- Anatomical Site -- Second Primary vs Recurrent Tumors -- Re-Irradiation after Salvage Surgery ---
001895659
express
(Au-PeEL)EBL6636681
(MiAaPQ)EBC6636681
(OCoLC)1256238606

Zvolte formát: Standardní formát Katalogizační záznam Zkrácený záznam S textovými návěštími S kódy polí MARC